Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxytocin and Lorazepam Effects on Fear Neurocircuitry
NCT03829839Phase 1Completed
- Sponsor
- University Hospital Bonn
- Start
- Mar 2016
- Primary completion
- Aug 2017
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of oxytocin nasal spray in anxiety disorders (3 arms), sponsored by University Hospital Bonn. Primary endpoint: Neural responses to emotional faces in the amygdala subregions. Started Mar 2016; status: completed.
02
Drugs
oxytocin nasal spray
03
Conditions
anxiety disorders
Beyond the preview
Go deeper on NCT03829839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03829839.